Some of the newly discovered associations, e.g., those for TREX1, may suggest potential novel direct drug targets in tumors with residual TREX1 expression, and also add to the accumulating body of evidence about the importance of upregulation of the cGAS/STING pathway in treatment of cancer patients [79, 80, 85]. The gene discussed is TREX1; the disease is cancer.